Antibodies
BMS-833923
- 貨號 Cat. No.
- S7138
- 規格 Size
- 10mgã€50mg
- 品牌 Brand
- Selleckchem
Description
BMS-833923
Catalog No.S7138
BMS-833923 is an orally bioavailable Smoothened antagonist. Phase 2.
| Size | Price | Stock | Quantity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | BMS-833923 is an orally bioavailable Smoothened antagonist. Phase 2. | |||||
|---|---|---|---|---|---|---|
| Targets | Smoothened | |||||
| IC50 | [1] | |||||
| In vitro | BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. [2] BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. [3] | |||||
| In vivo | ||||||
| Features | ||||||
Protocol(Only for Reference)
References
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00909402 | Completed | Stomach Neoplasms|Esophageal Neoplasms | Bristol-Myers Squibb|Exelixis | 2009-11 | Phase 1 |
| NCT00927875 | Completed | Small Cell Lung Carcinoma | Bristol-Myers Squibb|Exelixis | 2010-02 | Phase 1 |
| NCT01218477 | Completed | Leukemia | Bristol-Myers Squibb | 2011-01 | Phase 1|Phase 2 |
| NCT01357655 | Active, not recruiting | Leukemia | Bristol-Myers Squibb | 2011-09 | Phase 2 |
| NCT01413906 | Completed | Cancer | Bristol-Myers Squibb | 2011-11 | Phase 1 |
Chemical Information
| Molecular Weight (MW) | 473.57 |
|---|---|
| Formula | C30H27N5O |
| CAS No. | 1059734-66-5 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | XL139 |
| Solubility (25°C) * | In vitro | DMSO | 95 mg/mL (200 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | Benzamide, N-[2-methyl-5-[(methylamino)methyl]phenyl]-4-[(4-phenyl-2-quinazolinyl)amino]- |
|---|
